CSL Stock

CSL Net Income

Delisted·Jun 19, 2026

The Net Income of CSL (CSL.AX) as of Jul 24, 2026 is 3.00 B USD. In the previous year, Net Income was 2.64 B USD — a change of 13.63% (higher).

Net Income

3.00 BUSD

YoY

13.63%

Last updated:

In 2026, CSL's profit amounted to 3.00 B USD, a 13.63% increase from the 2.64 B USD profit recorded in the previous year.

The CSL Net Income history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

NET INCOME (B USD)
Date
NET INCOME (B USD)
Jan 1, 2024
2.64 base
Jan 1, 2025
3.00 base
Jan 1, 2026 (e)
3.40 base
Jan 1, 2027 (e)
3.67 base
Jan 1, 2028 (e)
3.96 base
Jan 1, 2029 (e)
4.41 base
Jan 1, 2030 (e)
4.75 base
Jan 1, 2031 (e)
5.07 base
YEARNET INCOME (B USD)
2031 est 5.07
2030 est 4.75
2029 est 4.41
2028 est 3.96
2027 est 3.67
2026 est 3.40
2025 3.00
2024 2.64
2023 2.19
2022 2.25
2021 2.38
2020 2.10
2019 1.92
2018 1.73
2017 1.34
2016 1.24
2015 1.38
2014 1.31
2013 1.22
2012 1.01
2011 0.94
2010 0.93
2009 0.84
2008 0.63
2007 0.42
2006 0.09
Access this data via the Eulerpool API

CSL Revenue

CSL Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2024
14.80 B USD
3.81 B USD
2.64 B USD
Jan 1, 2025
15.56 B USD
4.10 B USD
3.00 B USD
Jan 1, 2026 (e)
16.00 B USD
4.86 B USD
3.40 B USD
Jan 1, 2027 (e)
16.66 B USD
5.12 B USD
3.67 B USD
Jan 1, 2028 (e)
17.46 B USD
5.44 B USD
3.96 B USD
Jan 1, 2029 (e)
19.12 B USD
5.70 B USD
4.41 B USD
Jan 1, 2030 (e)
20.85 B USD
5.94 B USD
4.75 B USD
Jan 1, 2031 (e)
22.03 B USD
0.00 USD
5.07 B USD

CSL Margins

CSL stock margins

The CSL margin analysis displays the gross margin, EBIT margin, as well as the profit margin of CSL. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for CSL.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2024
51.83 %
25.76 %
17.85 %
Jan 1, 2025
51.93 %
26.38 %
19.30 %
Jan 1, 2026 (e)
51.93 %
30.39 %
21.27 %
Jan 1, 2027 (e)
51.93 %
30.71 %
22.05 %
Jan 1, 2028 (e)
51.93 %
31.16 %
22.69 %
Jan 1, 2029 (e)
51.93 %
29.82 %
23.09 %
Jan 1, 2030 (e)
51.93 %
28.50 %
22.80 %
Jan 1, 2031 (e)
51.93 %
0.00 %
23.01 %

CSL Stock analysis

What does CSL do? CSL Ltd is a global leading company in the field of biological medicine, manufacturing a wide range of products used in the therapy of diseases. The company is based in Melbourne, Australia, and is one of the largest biotech companies in the country. CSL was founded in 1916 by Australian researcher Frank Macfarlane Burnet. Originally named Commonwealth Serum Laboratories, the company focused on the research and production of vaccines. CSL was then privatized in 1994 and changed its name to CSL Ltd. CSL's business model is based on the production of protein products and plasma derivatives used in immunotherapy, hematology, and transplantation medicine. The company specializes in the production and marketing of products in three main areas: plasma products, vaccines, and animal health. CSL's plasma division includes a variety of products, including intravenous immunoglobulins (IVIG), platelets, and alpha-1 antitrypsin. The company operates a number of plasma centers in the US and Europe to collect raw materials for these products. In the vaccine sector, CSL is primarily involved in the manufacture of influenza vaccines and also offers a range of other vaccines, including vaccines against snake bites and encephalitis. In the field of animal health, CSL produces animal vaccines to prevent viral infections in livestock such as pigs, poultry, and cattle. CSL is committed to research and development to develop new products and improve existing ones. The company has a long history in the research and development of vaccines and immunotherapies and has established a strong presence in this field. The company employs over 27,000 people in 35 countries worldwide and operates production facilities in Australia, the US, Europe, and Asia. CSL's headquarters are located in Parkville, a suburb of Melbourne, Australia. CSL has an impressive track record in terms of growth and profitability and is a stable market leader in its field. The company has achieved solid growth rates in recent years and generated a revenue of $8.5 billion in 2019. CSL is a key player in the global healthcare industry and has established a reputation as a reliable supplier of medical products and services. The company is committed to developing innovative solutions to advance medical progress and make a positive contribution to human health. CSL is one of the most popular companies on Eulerpool.

Net Income Details

Understanding CSL's Profit Margins

The profit margins of CSL represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of CSL's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating CSL's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

CSL's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When CSL’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about CSL stock

Net Income of CSL is 3.00 B USD in 2026.

The profit in evaluating a stock

History, usage, calculation, and application of earnings in securities trading.

The history of earnings dates back to the beginnings of modern business organization. Since the beginning of industrialization, companies have been established to generate profits, and profits have been considered an essential part of corporate management. In recent years, the importance of earnings for investors has continued to rise, as many investors seek to find stocks that generate solid earnings.

Use of Profits

In securities trading, profits are used to determine the value of a stock. A company that generates profits is considered financially healthy and its stocks are valued higher, while a company that does not generate profits is considered less reliable and therefore receives a lower valuation. Investors can review the profits of each company by examining the relevant documents such as the income statement, the annual financial statements, and the income tax audits.

Calculation of profits

There are several different ways to calculate profits. The simplest way to calculate profits is by calculating net earnings. Net earnings are calculated by subtracting the company's expenses from its revenue. Another way to calculate profits is by calculating operating income. Operating income is calculated by subtracting the company's materials costs and employee wages and salaries from its revenue.

Use of profits

There are many different ways in which investors can use profits when evaluating stocks. One example is calculating the price-to-earnings ratio (P/E ratio). The P/E ratio is the relationship between the price of a stock and the company's earnings. When calculating the P/E ratio, the stock price is divided by the company's earnings. A low P/E value indicates that the stock has a good price-performance ratio, and a high P/E value indicates that the stock has a poor price-performance ratio.

Advantages and disadvantages of using profits

There are many advantages to using earnings in securities trading. Firstly, investors can check the financial health of a company by analyzing earnings. Secondly, investors can make a better decision about the valuation of a stock by calculating the P/E ratio. Thirdly, investors can reduce their risk by choosing stocks with a low P/E ratio.

However, there are also some drawbacks to relying on profits. Firstly, profits can be distorted if a company increases its profits through cost-cutting measures. Secondly, profits can present an inaccurate picture of a company's financial health if they are not calculated correctly. Thirdly, profits may not always be a reliable indicator of a company's future, as they can easily fluctuate.

t('components_kpi_Explanation_34')

Overall, it can be said that profits in securities trading are an important indicator of a company's financial health. Investors can analyze profits to get a better understanding of the company's financial health and make informed decisions about stock valuation. However, there are some disadvantages to using profits as they can sometimes be distorted or inaccurate. Therefore, it is important for investors to be cautious and carefully analyze profits before making a decision to buy or sell stocks.

Access this data via the Eulerpool API

Income Statement — CSL

All Key Metrics — CSL